Cost-Effectiveness of Early Initiation of Fingolimod Versus Delayed Initiation After 1 Year of Intramuscular Interferon Beta-1a in Patients with Multiple Sclerosis

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1583-1590

  Agashivala, Neetu ^a   Kim, Edward ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cost effectiveness; Fingolimod; Interferon; Multiple sclerosis; Treatment

Indexed keywords

ANALYSOURCE; BETA1A INTERFERON; FINGOLIMOD; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SENSITIVITY ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863835433     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.012     Document Type: Article

References (33)

1. Woo D.A., Olek M.J., Frohman E.M. Diagnosis and management of multiple sclerosis: case studies. Neurol Clin 2006, 24:199-214.
2. Shapiro R.T. Managing symptoms of multiple sclerosis. Neurol Clin 2005, 23:177-187.
3. Lad S.P., Chapman C.H., Vaninetti M., et al. Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology 2010, 35:93-99.
4. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011, 76:S14-S25.
5. Lublin F.D., Baier M., Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003, 61:1528-1532.
6. Interferon beta-1α for intramuscular injection 2011, [package insert], Biogen Idec, Inc, Cambridge, Mass.
7. Rebif 2011, [package insert], EMD Serono, Inc, Rockland, Mass.
8. Betaseron 2010, [package insert], Bayer HealthCare Pharmaceuticals, Inc, Montville, NJ.
9. Extavia 2009, [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ.
10. Copaxone 1998, [package insert], Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel.
11. Tysabri 2012, [package insert], Biogen Idec, Inc, Cambridge, Mass.
12. Gilenya 2012, [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ.
13. Kappos L., Radue E.-W., O'Connor P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
14. Cohen J.A., Barkhof F., Comi G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
15. Khatri B., Barkhof F., Comi G., et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomized extension of the TRANSFORMS study. Lancet Neurol 2011, 10:520-529.
16. Agashivala N.V., Dastani H.B., Carlton R., Sarnes E. Cost-effectiveness of fingolimod in treating patients with relapsing-remitting multiple sclerosis. Am J Pharm Benefits 2011, 3:320-328.
17. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33. 1444-1152.
18. Carra A., Onaha P., Sinay V., et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 2003, 10:671-676.
19. AnalySource, Accessed August 2011. https://www1.analysource.com/qry/as_products.taf?_purgefilter=Y%26_nc=ee630cd74f711729196667e52744f70c.
20. Beckerman H., van Zee I.E., de Groot V., et al. Utilization of health care by patients with multiple sclerosis is based on professional and patient-defined health needs. Mult Scler 2008, 14:1269-1279.
21. Physician's Fee and Coding Guide 2010, MAG Mutual HealthCare Solutions, Inc, Duluth, Ga.
22. O'Brien J.A., Ward A.J., Patrick A.R., Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003, 3:17.
23. Joyce A.T., Iacoviello J.M., Nag S., et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2004, 27:2829-2835.
24. Miller R.M., Happe L.E., Meyer K.L., Spear R.J. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm 2012, 18:54-62.
25. Carra A., Onaha P., Luetic G., et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008, 15:386-393.
26. Castillo-Trivino T., Mowry E.M., Gajofatto A., et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One 2011, 6:e16664.
27. Rio J., Tinore M., Sastre-Garriga J., et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 2012, 19:899-904.
28. Prosperini L., Gianni C., Leonardi L. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012, 18:64-71.
29. Sormani M.P., Bonzano L., Roccatagliata L., et al. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology 2010, 75:302-309.
30. Waters T.M., Weinberg P.D., Bennett C.L. Health economics in the treatment of colorectal cancer. Cancer Invest 1998, 16:582-587.
31. Costello K., Kennedy P., Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008, 10:225.
32. Friedberg M., Saffran B., Stinson T.J., et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999, 282:1453-1457.
33. Knox K.S., Adams J.R., Djulbegovic B., et al. Reporting and dissemination of industry versus non-profit sponsored economic analysis of six novel drugs used in oncology. Ann Oncol 2000, 11:1591-1595.